First BMD Patients Dosed in Trial of Oral Therapy EDG-5506

First BMD Patients Dosed in Trial of Oral Therapy EDG-5506

310921

First BMD Patients Dosed in Trial of Oral Therapy EDG-5506

A Phase 1 clinical trial evaluating Edgewise Therapeutics’ experimental oral therapy EDG-5506 in healthy volunteers and men with Becker muscular dystrophy (BMD) has dosed the first BMD patients. The study (NCT04585464) is currently recruiting up to eight men, ages 18 to 55, with BMD at its single site in San Antonio, Texas; more information can be found here. Top-line data from these patients are expected by the end of the year. The initiation of patient dosing…

You must be logged in to read/download the full post.